MedTrace Logo

Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis

NCT06328075 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 15000

Last updated 2024-03-25

No results posted yet for this study

Summary

The goal of this study is to develop an algorithm using artificial intelligence (AI) to assist identification of potential ATTR-CM cases using routine transthoracic echocardiography.

The main questions it aims to answer are:

* is the algorithm able to diagnose ATTR-CM
* is the algorithm able to diagnose different types of ATTR-CM (ATTRv, ATTRwt)

This is a non interventional study. Participant' echocardiographies will be, after deidentification, used to train, valid and test the algorithm.

Conditions

  • Amyloid Cardiomyopathy
  • Transthyretin Amyloid Cardiomyopathy
  • Transthyretin Cardiac Amyloidosis

Interventions

OTHER

non interventional study

non interventional study

Sponsors & Collaborators

  • Bichat Hospital

    collaborator OTHER

  • Bioquantis

    collaborator UNKNOWN

  • Algalarrondo Vincent

    lead OTHER

Principal Investigators

  • Gabriel Steg, MD, PhD · Bichat Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2025-01-01
Completion
2026-01-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06328075 on ClinicalTrials.gov